CGM097

Overview

CGM097 is an orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | MDM-2, p53

Product Information

• Catalog No.: B0084-462483
• CAS No.: 1313363-54-0
• Molecular Formula: C38H47ClN4O4
• Molecular Weight: 659.27
• Storage: Store at -20°C

Source

Original product source